Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

231 results about "Survivin" patented technology

Survivin, also called baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5, is a protein that, in humans, is encoded by the BIRC5 gene. Survivin is a member of the inhibitor of apoptosis (IAP) family. The survivin protein functions to inhibit caspase activation, thereby leading to negative regulation of apoptosis or programmed cell death. This has been shown by disruption of survivin induction pathways leading to increase in apoptosis and decrease in tumour growth. The survivin protein is expressed highly in most human tumours and fetal tissue, but is completely absent in terminally differentiated cells. These data suggest survivin might provide a new target for cancer therapy that would discriminate between transformed and normal cells. Survivin expression is also highly regulated by the cell cycle and is only expressed in the G2-M phase. It is known that Survivin localizes to the mitotic spindle by interaction with tubulin during mitosis and may play a contributing role in regulating mitosis. The molecular mechanisms of survivin regulation are still not well understood, but regulation of survivin seems to be linked to the p53 protein. It also is a direct target gene of the Wnt pathway and is upregulated by beta-catenin.

Method for effectively culturing tumor infiltrating lymphocytes (TILs)

InactiveCN102174469AShorter hospital stayReduce the burden of hospitalizationBlood/immune system cellsAntineoplastic agentsClinical efficacyApoptosis Regulatory Proteins
The invention discloses a method for effectively culturing tumor infiltrating lymphocytes (TILs). The method comprises the following steps: extracting mononuclear cells from the pectoral ascite or tumor tissue of a patient, washing, inoculating into a culture bottle coated with recombinant human fibrin and cluster-of-differentiation-3 antibody, culturing for 24 hours, adding interleukin II, then using a serum-free culture medium containing the interleukin II and the supernatant pectoral ascite to enlarge and subculture every two or three days, and adding apoptosis-regulated protein survivin and mucoprotein-1 on the twelveth or thirteenth day to activate the killing activity; and harvesting cells on the fourteenth day. By adopting the method, the culture time, which is only 14 days, is greatly shortened, so that the hospital stays of the patient can be greatly shortened and the hospital burden of the patient can be reduced. Meanwhile, the problems that the cell proliferation speed is low and the proliferation ratio is low can be solved, thus the number of the cultured cells can meet the clinical requirement. The cultured TILs has strong cell specificity so as to enhance the clinical curative effect.
Owner:宋鑫 +1

Kit for jointly detecting breast cancer 21 genes and preparation method of kit

InactiveCN104004844AEasy to operateShorten detection experiment timeMicrobiological testing/measurementSingle sampleBAG1
The invention discloses a kit for jointly detecting breast cancer 21 genes. A PCR (polymerase chain reaction) amplification primer consists of 21 primer pairs, and can be used for jointly detecting 21 gene-related expression quantities: Ki67, STK15, Survivin, CCNB1, MYBL2, MMP11, CTSL2, GRB7, HER2, GSTM1, CD68, BAG1, ER, PGR, BCL2, SCUBE2, ACTB, GAPDH, PRLPO, GUS, and TFRC. Output fragments of the 21 pairs of primers related in the invention are smaller than 100bp, so that PCR efficiency after reverse transcription of mRNA (messenger ribonucleic acid) extracted by a paraffin specimen is greatly improved, all primers of 21 genes are premixed, and time and labor for designing and synthesizing 21 pairs of genes by an experimenter are saved; the corresponding primers of the 21 genes are not needed to be added for premixing in mother liquor, and therefore, errors of reaction holes are greatly reduced. The kit disclosed by the invention is simple to operate, and capable of detecting on a quantitative PCR instrument by only adding a template, so that detection experimental time is greatly shortened. The kit disclosed by the invention is applicable to a single sample and multiple samplers, so that results can be quickly obtained, and therefore, scientific research and clinical detection requirements can be satisfied very well.
Owner:杭州美中疾病基因研究院有限公司

Survivin-directed RNA interference-compositions and methods

InactiveUS20060276423A1Poor prognosis of survivalHigh sensitivityBiocideOrganic active ingredientsDiseaseDNA
The present invention is directed to compositions and methods for inhibiting the expression of survivin in cells expressing survivin. The invention is also directed to methods of treating conditions associated with elevated survivin, such as hyperproliferative disorders. More particularly, the invention is directed to inhibition of survivin expression using short interfering RNAs (si-RNAs) or through administration of DNA sequences yielding the expression of short hairpin RNAs (sh-RNAs).
Owner:ALTURA RACHEL +2
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products